The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials
Abstract
STUDY OBJECTIVE In this study, we performed a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials to evaluate the efficacy and safety of eszopiclone for the treatment of primary insomnia. METHODS We searched MEDLINE, EMBASE, PsycINFO, Cochrane Central Register of Controlled Trials and PubMed from inception to June 2018. Additionally, we searched the ClinicalTrials.gov trials register for other relevant trials. According to participants, intervention, comparison, outcome (PICO) criteria, studies were included that focused on: adults diagnosed with primary insomnia, aged 18-65 and > 65 years; eszopiclone for the treatment of primary insomnia; comparison were made between eszopiclone and placebo; as well as primary outcomes, secondary outcomes, and adverse effects. RESULTS A total of six randomized trials involving 2809 patients with primary insomnia were included in our analysis. Our analysis suggested that eszopiclone was associated with significant improvements in subjective sleep latency, wake after sleep onset, number of awakenings, total sleep time at one week, two weeks, one month, three months and six months. Meanwhile, eszopiclone was associated with increased quality of sleep, ability to function, daytime alertness and sense of physical well-being at one week, one month, three months and six months. Dizziness and unpleasant taste were the most common adverse effects in elderly subgroup. Alternately, non-elderly patients may be more prone to adverse effects such as infection, pharyngitis, somnolence, unpleasant taste and dry mouth. CONCLUSION This meta-analysis showed that eszopiclone is an effective and safe therapy option for patients with primary insomnia, especially in elderly patients. However, due to the high clinical heterogeneity in some outcomes, further standardized preparation, large-scale and rigorously designed trials are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Beyond that timeframe, the meta-analyses by Liang et al. (2019) and Rösner et al. (2018) suggest positive effects of eszopiclone for a period of application of up to 6 months in certain cases, but this is to be decided on an individual basis.”
From The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023 (2023) · cites this paper as Liang et al. (2019)
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943
Huedo-Medina, T. B., Kirsch, I., Middlemass, J., Klonizakis, M., & Siriwardena, A. N. (2012) · BMJ · doi:10.1136/bmj.e8343 · Cited by 313
Buysse, D. J., Reynolds, C. F., Kupfer, D. J., Thorpy, M. J., Bixler, E., Manfredi, R., Kales, A., Vgontzas, A., Stepanski, E., Roth, T., et al. (1994) · Sleep · doi:10.1093/sleep/17.7.630 · Cited by 274
Walsh, J. K., Krystal, A. D., Amato, D. A., Rubens, R., Caron, J., Wessel, T. C., Schaefer, K., Roach, J., Wallenstein, G., & Roth, T. (2007) · Sleep · doi:10.1093/sleep/30.8.959 · Cited by 239
Research works printed but not linked: 26
- Ohayon, 2002, Epidemiology of insomnia: what we know and what we still need to learn, Sleep Med Rev, 6, 97, 10.1053/smrv.2002.0186 · DOI · Paper page
- Wilt, 2016, Pharmacologic treatment of insomnia disorder: an evidence report for a clinical practice guideline by the American college of physicians, Ann Intern Med, 165, 103, 10.7326/M15-1781 · DOI · Paper page
- Benca, 2005, Diagnosis and treatment of chronic insomnia: a review, Psychiatr Serv, 56, 332, 10.1176/appi.ps.56.3.332 · DOI · Paper page
- McCrae, 2007, Eszopiclone for late-life insomnia, Clin Interv Aging, 2, 313
- Owen, 2011, Eszopiclone: an update on its use in insomnia, Drugs Today, 47, 263, 10.1358/dot.2011.47.4.1590792 · DOI
- Wessell, 2005, Eszopiclone (Lunesta) for treatment of transient and chronic insomnia, Am Fam Phys, 71, 2359
- Rosenberg, 2005, An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults, Sleep Med, 6, 15, 10.1016/j.sleep.2004.09.001 · DOI
- Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, Ann Intern Med, 151, W65, 10.7326/0003-4819-151-4-200908180-00136 · DOI · Paper page
- Uchimura, 2012, A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia, Sleep Med, 13, 1247, 10.1016/j.sleep.2012.08.015 · DOI
- Shamseer, 2015, Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation, BMJ, 350, g7647, 10.1136/bmj.g7647 · DOI · Paper page
- Pichot, 1986, DSM-III: the 3d edition of the diagnostic and statistical manual of mental disorders from the American psychiatric association, Revue neurologique, 142, 489
- Kasahara, 1981, DSM-III (diagnostic and statistical manual of mental disorders, the 3d edition), a new diagnostic criteria in the United States, Seishin shinkeigaku zasshi Psychiatria et neurologia Japonica, 83, 607
- Slee, 1978, The international classification of Diseases: ninth revision (ICD-9), Ann Intern Med, 88, 424, 10.7326/0003-4819-88-3-424 · DOI · Paper page
- Ebner, 2018, From meta-analysis to Cochrane reviews, J Cachexia Sarcopenia Muscle, 9, 441, 10.1002/jcsm.12312 · DOI
- Riley, 2013, Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data, Stat Med, 32, 2747, 10.1002/sim.5726 · DOI
- Krystal, 2003, Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia, Sleep, 26, 793, 10.1093/sleep/26.7.793 · DOI · Paper page
- McCall, 2006, A polysomnography study of eszopiclone in elderly patients with insomnia, Curr Med Res Opin, 22, 1633, 10.1185/030079906X112741 · DOI
- Zammit, 2004, Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia, Curr Med Res Opin, 20, 1979, 10.1185/174234304X15174 · DOI · Paper page
- Ancoli-Israel, 2010, A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia, Sleep, 33, 225, 10.1093/sleep/33.2.225 · DOI
- Scharf, 2005, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia, Sleep, 28, 720, 10.1093/sleep/28.6.720 · DOI
- Buscemi, 2005, The efficacy and safety of exogenous melatonin for primary sleep disorders. A meta-analysis, J Gen Intern Med, 20, 1151, 10.1111/j.1525-1497.2005.0243.x · DOI · Paper page
- Ferracioli-Oda, 2013, Meta-analysis: melatonin for the treatment of primary sleep disorders, PLoS One, 8, 10.1371/journal.pone.0063773 · DOI · Paper page
- Owen, 2011, Eszopiclone: an update on its use in insomnia, Drugs Today (Barc), 47, 263, 10.1358/dot.2011.47.4.1590792 · DOI
- Barbone, 1998, Association of road-traffic accidents with benzodiazepine use, Lancet, 352, 1331, 10.1016/S0140-6736(98)04087-2 · DOI · Paper page
- Verster, 2006, Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test, Curr Drug Saf, 1, 63, 10.2174/157488606775252674 · DOI
- Uemura, 2015, Residual effects of zolpidem, triazolam, rilmazafone and placebo in healthy elderly subjects: a randomized double-blind study, Sleep Med, 16, 1395, 10.1016/j.sleep.2015.05.021 · DOI
Cited by
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
“Beyond that timeframe, the meta-analyses by Liang et al. (2019) and Rösner et al. (2018) suggest positive effects of eszopiclone for a period of application of up to 6 months in certain cases, but this is to be decided on an individual basis.”
MethodLeichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association
Drager, L. F., Assis, M., Bacelar, A. F. R., Poyares, D. L. R., Conway, S. G., Pires, G. N., de Azevedo, A. P., Carissimi, A., Eckeli, A. L., Pentagna, Á., et al. (2023) · Sleep Science · doi:10.1055/s-0043-1776281 · Cited by 25
Metadata
- Authors
- Liang, L., Huang, Y., Xu, R., Wei, Y., Xiao, L., & Wang, G.
- Venue
- Sleep Medicine
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 62
- Pages
- 6-13
- ISSN
- 1389-9457
- Cited by
- 32
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. https://app.cochat.ai/papers/10.1016/j.sleep.2019.03.016
- The paper
- Liang, L., Huang, Y., Xu, R., Wei, Y., Xiao, L., & Wang, G. (2019). Eszopiclone for the treatment of primary insomnia: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials. Sleep Medicine. https://doi.org/10.1016/j.sleep.2019.03.016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.